Tocilizumab has received approval in Europe and the United States (January 2009 and 2010, respectively) for the treatment of moderate to severe RA in adult patients who have responded inadequately or have been intolerant to previous therapy with one or more DMARDs or TNF antagonists. This evidence concerns the gene TNF and rheumatoid arthritis.